The Bone That Fights Back

New Discoveries in Canine Osteosarcoma

The Diagnosis Nobody Wants:

It starts with a limp. The owner notices it first, a subtle favouring of one leg, easily dismissed as a sprain or a pulled muscle. But the limp doesn't go away. It gets worse. And when the X-ray comes back, the image tells a story that no veterinarian enjoys delivering: a sunburst pattern of bone destruction at the distal radius or proximal humerus, the hallmark of osteosarcoma (Fig 1).

Canine osteosarcoma is the most common primary bone tumour in dogs, affecting 10,000 to 15,000 dogs annually in the United States alone. It strikes large and giant breeds disproportionately, Scottish Deerhounds, Irish Wolfhounds, Rottweilers, Great Danes, Golden Retrievers; dogs with long legs and a longer skull conformation are 30 to 100 times more commonly affected than crossbreeds. And it is brutal. An estimated 90% of canine patients have microscopic metastatic lesions at the time of diagnosis. Most die from metastatic disease within a year.

For more than three decades, the standard of care has not changed: amputation of the affected limb, followed by adjuvant platinum-based chemotherapy (most commonly carboplatin or cisplatin).

Figure 1. Orthogonal clinical and radiographic views of canine appendicular osteosarcoma. Image generated by the author using AI for illustrative purposes.

Median survival with amputation alone is approximately 134 days. With chemotherapy, it extends to 200 to 480 days. That is not a cure. It is a reprieve, and for many owners, it is not enough to justify the cost, the surgery, or the suffering.

But in 2025 and 2026, something is shifting. A wave of immunotherapy research, vaccines, adoptive cell therapies, checkpoint inhibitors, and microenvironment modifying strategies is beginning to change what is possible for dogs with osteosarcoma. And because canine OSA is biologically near-identical to human osteosarcoma, every advance in the dog is also an advance for the adolescents and young adults diagnosed with this disease in humans every year. This is the story of that revolution.

The Immune System Was Always the Answer:

The idea that the immune system could control osteosarcoma is not new. In the 19th century, the surgeon William B. Coley observed that some bone sarcoma patients who developed concurrent bacterial infections experienced spontaneous tumour remissions. He developed 'Coley's toxins' a mixture of bacterial species, and reported anecdotal successes (the world's first systemic cancer immunotherapy). The mechanism was not understood at the time, but the observation was real: activating the immune system could, in some patients, control bone cancer.

More than a century later, veterinary researchers made a strikingly similar observation. Dogs with osteosarcoma who developed surgical site infections following limb-sparing surgery had significantly prolonged disease-free intervals compared to dogs without infection. The immune activation triggered by the infection appeared to be attacking the cancer at the same time.

A 2026 review by Edmunds and Mason in the Rare Diseases and Orphan Drugs Journal synthesised the entire body of immunotherapy research in canine OSA and identified the key biological insight underpinning all of it: dogs whose tumours are infiltrated with cytotoxic T cells and natural killer (NK) cells, so-called 'hot' or 'immune-enriched' tumours, have a significant survival advantage over dogs with 'cold' or 'immune desert' tumours devoid of immune cells. The immune system can control osteosarcoma. The challenge is getting it to do so reliably.

🔬 KEY INSIGHT: Dogs with 'hot' tumours, infiltrated with cytotoxic T cells and NK cells, have significantly better survival than those with 'cold' tumours. This is the biological rationale for all immunotherapy approaches in OSA.

The Personalised Cancer Vaccine That Works:

Of all the immunotherapy approaches being tested in canine osteosarcoma, the one with the most mature clinical data, and the only one with USDA regulatory approval is the ELIAS Cancer Immunotherapy, or ECI. It is an autologous, personalised treatment: after amputation, tumour cells are collected from the removed limb and used to manufacture a series of personalised cancer vaccines, specific to that individual dog's tumour. Those vaccines prime the dog's own T cells to recognise and attack the cancer. The primed T cells are then expanded outside the body and reinfused; a process called adoptive cell therapy, to deliver a targeted immune assault against any remaining tumour cells.

ECI is distributed under an Autologous Prescription Product licence issued by the USDA, making it the first immunotherapy approved for canine osteosarcoma. But the most compelling data comes from the ASCENT study, whose 18-month interim analysis was presented at the VCS/VSSO Collaborative Conference in Savannah, Georgia, in March 2026.

The ASCENT study enrolled 13 dogs with newly diagnosed appendicular osteosarcoma. After amputation, each dog received a single dose of carboplatin chemotherapy, followed by the full ECI protocol initiated approximately 21 days later. Survival outcomes were compared to a matched historical control group of dogs who received the standard four-dose carboplatin protocol.

A note of scientific honesty is essential here. The ASCENT study enrolled 13 dogs and compared them to a historical control group, not a concurrent randomised control arm. This is a meaningful limitation. Historical comparisons are subject to selection bias, and the small sample size means the confidence intervals are wide. The results are compelling and hypothesis-generating, but they require validation in a larger, properly randomised prospective trial before ECI can be considered a new standard of care.

Teaching the Immune System to Recognise Cancer:

A different immunotherapy approach, one that does not require personalised manufacturing from each individual dog's tumour, is the Listeria-based cancer vaccine. The concept is elegant: engineer a weakened strain of Listeria monocytogenes to express a tumour-associated antigen, then administer it as a vaccine. The bacterial vector activates the innate immune system powerfully, while the expressed antigen trains the adaptive immune system to recognise and attack cells carrying that antigen, including cancer cells.

In canine osteosarcoma, the target antigen is HER2, a protein overexpressed on the surface of OSA cells. A landmark study published in Molecular Therapy in April 2025 evaluated immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy (amputation plus carboplatin) combined with a Listeria vaccine expressing HER2. The study demonstrated measurable immunological responses, evidence that the vaccine was successfully training the immune system to recognise HER2-expressing cells, alongside clinical outcome data in treated dogs.

A follow-up study, published in Molecular Therapy Oncology in June 2026, took this approach a step further by combining radiation therapy with the Listeria immunotherapy. The rationale is mechanistically sound: radiation kills tumour cells and releases tumour antigens into the local environment, effectively 'priming' the immune system with a burst of cancer-specific signals. The Listeria vaccine then amplifies and directs that immune response. The 2026 study demonstrated that this combination induces cytotoxic immunity, measurable activation of cancer-killing T cells, that correlates with improved clinical outcomes in treated dogs.

The Listeria vaccine approach has a practical advantage over other personalised therapie: it is an off-the-shelf product, not manufactured individually for each patient. If it proves effective in larger trials, it could be deployed far more widely and affordably than autologous cell therapies.

Reading the Cancer's Blueprint:

Immunotherapy is only as good as our understanding of the tumour it is targeting. And for osteosarcoma, a disease characterised by genomic chaos, large structural rearrangements, and no single dominant driver mutation, that understanding has been frustratingly incomplete. A landmark study published in Clinical Cancer Research in August 2026 by Garg and colleagues is beginning to change that.

The study presents the first multiomic dataset created from a large, outcome-linked biobank of canine osteosarcoma treatment-naïve primary tumours. 'Multiomic' means the researchers analysed multiple layers of biological information simultaneously: genomics (DNA mutations and copy number alterations), transcriptomics (gene expression), epigenomics (DNA methylation patterns), and the tumour immune microenvironment. By integrating these datasets, they could identify patterns that no single analysis would reveal.

The findings are clinically significant. MYC amplification, a well-known oncogene, emerged as a poor prognostic indicator in canine OSA, a finding that mirrors and reinforces data from human osteosarcoma research. The study also identified alterations in DNA damage repair, metabolism, and cell-cycle genes that are shared between dogs and humans, further validating the dog as a translational model. Crucially, the researchers identified relationships between the local tumour immune microenvironment, TP53 mutations, MYC and PTEN status, and global gene methylation patterns, connections that could inform which patients are most likely to respond to immunotherapy.

This work matters because it provides the molecular framework that precision oncology requires. Instead of treating every dog with OSA the same way, future clinicians may be able to stratify patients by their tumour's molecular profile, identifying which dogs are most likely to respond to immunotherapy, which have druggable targets, and which require a different approach entirely. Outcomes in osteosarcoma have not improved in over 30 years. Multiomic profiling is the foundation for changing that.

The Broader Immunotherapy Landscape:

ECI and the Listeria vaccine are the most clinically advanced immunotherapy approaches in canine OSA, but they are not the only ones. The 2026 review by Edmunds and Mason catalogued the full landscape of emerging strategies, each targeting a different aspect of the immune response.

Checkpoint inhibitors, drugs that block the PD-1/PD-L1 axis that cancer cells use to suppress immune attack, are being investigated in canine OSA, mirroring their transformative role in human oncology. Invariant natural killer T (iNKT) cells, a specialised immune cell population with potent anti-tumour activity, are being explored as a cellular therapy approach. Losartan, an angiotensin II receptor blocker more commonly used for blood pressure, is being investigated for its ability to reduce the immunosuppressive extracellular matrix that surrounds OSA tumours and prevents immune cells from penetrating them. And mifamurtide, a synthetic analogue of bacterial cell wall components that activates macrophages and monocytes, has shown activity in human osteosarcoma and is being evaluated in dogs, this is while this drug has received European Medicines Agency for treatment of high-grade, resectable, non-metastatic osteosarcoma in pediatric and young adult cohorts. What unites all of these approaches is the same biological insight: osteosarcoma is not invisible to the immune system. It actively suppresses immune attack through multiple mechanisms, creating an immunosuppressive tumour microenvironment, expressing checkpoint ligands, recruiting regulatory T cells. The therapeutic goal is to reverse that suppression and unleash the immune response that the tumour has been blocking.

Figure 2. Orthogonal clinical and radiographic views of canine appendicular osteosarcoma. Image generated by the author using AI for illustrative purposes.

Two Species, One Disease:

There is something profound about the relationship between canine and human osteosarcoma research. In humans, OSA is rare, roughly 0.2% to 3% of primary tumors. That rarity makes clinical trials extraordinarily difficult. Enrolling enough patients to power a randomised controlled trial takes years, sometimes decades. Progress is slow.

In dogs, OSA is common, the most common primary bone tumor in dogs (85 – 98% of all primary bone tumors). The disease is biologically near-identical: the same tumour suppressor pathways disrupted (TP53, RB1, PTEN), the same genomic instability, the same immune microenvironment dynamics, the same metastatic pattern to the lungs. Dogs and humans share the same environment, the same exposures, and the same immune system architecture. And dogs progress through the disease faster, meaning that a clinical trial in dogs can generate survival data in months that would take years to accumulate in human patients.

This is why the Edmunds and Mason review frames canine OSA research not just as veterinary medicine, but as translational medicine science that advances both species simultaneously. Every immunotherapy validated in dogs is a candidate for human clinical trials. Every biomarker identified in canine tumours is a hypothesis to test in human tumours. The dog is not just a patient. It is a research partner.